Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | CAR-T and allo-SCT: landscape for myeloma and DLBCL

Nicolaus Kröger • 4 Mar 2021
EBMT 2021
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Multiple Myeloma

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the current landscape of chimeric antigen receptor T-cell (CAR-T) therapy in the context of stem cell transplantation (SCT) for patients with multiple myeloma or diffuse large B-cell lymphoma (DLBCL). Prof. Kröger highlights upcoming results, comparing CAR-T and autologous-SCT in patients with DLBCL. Prof. Kröger shares that he anticipates an increase in the use of CAR-T in both advanced-stage and early-stage multiple myeloma in the near future. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals